يعرض 281 - 300 نتائج من 6,785 نتيجة بحث عن '(( significant fold decrease ) OR ( significant ((side decrease) OR (we decrease)) ))', وقت الاستعلام: 0.47s تنقيح النتائج
  1. 281
  2. 282
  3. 283
  4. 284
  5. 285
  6. 286
  7. 287

    Data Sheet 1_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.docx حسب Tianqi Xu (9574329)

    منشور في 2025
    "…</p>Results<p>In patients with LPD, we found reduced CSA in the right supramarginal gyrus (SMG), right precuneus (PCUN), left inferior parietal lobule (IPL), and left lingual gyrus (LING) compared to RPD, while no significant differences in CT were found between the two groups. …"
  8. 288

    Flow diagram of participants selection. حسب Wei Huang (36889)

    منشور في 2025
    "…Each10 units increase in BRI, ASM/ BMI decreased by 29% (β = −0.29,95% CI: −0.31, −0.28, <i><i>p</i></i> value < 0.0001). …"
  9. 289

    Minimal data set. حسب Wei Huang (36889)

    منشور في 2025
    "…Each10 units increase in BRI, ASM/ BMI decreased by 29% (β = −0.29,95% CI: −0.31, −0.28, <i><i>p</i></i> value < 0.0001). …"
  10. 290

    Weighted comparison of baseline characteristics. حسب Wei Huang (36889)

    منشور في 2025
    "…Each10 units increase in BRI, ASM/ BMI decreased by 29% (β = −0.29,95% CI: −0.31, −0.28, <i><i>p</i></i> value < 0.0001). …"
  11. 291
  12. 292

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX حسب Lihong Wang (14991)

    منشور في 2024
    "…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …"
  13. 293
  14. 294
  15. 295
  16. 296
  17. 297

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  18. 298

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  19. 299

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  20. 300